Adaptimmune Therapeutics PLC - ADR (OQ:ADAP)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
See Regulatory Filings on SEC
Company Contact
Address: 60 Jubilee Avenue
Tel: N/A
IR: See website
Key People
James Julian Noble
Chief Executive Officer, Director
Adrian Rawcliffe
Chief Financial Officer
William C. Bertrand
Chief Operating Officer
Sebastien Desprez
Vice President - Communications and Investor Relations
Paul Stead
Vice President - Business Development
Rafael Amado
Chief Medical Officer
Helen Katrina Tayton-Martin
Chief Business Officer
Business Overview
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company is developing multiple SPEAR T-cells to different target peptides in selected disease indications to increase the probability of treating patients with a given disease indication and potentially the ability for re-treatment of patients with a different SPEAR T-cell. It has three SPEAR T-cells in clinical trials, which are directed to cancer testis antigens, NY-ESO-1, MAGE-A4 and MAGE-A10.
Financial Overview
For the fiscal year ended 31 December 2018, Adaptimmune Therapeutics PLC - ADR revenues increased 57% to $59.5M. Net loss increased 36% to $95.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - other increase of 40% to $35.7M (expense), Research and development - Balancing val increase of 10% to $86.5M (expense).
Employees: 430 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $221.04M as of Dec 31, 2018
Annual revenue (TTM): $59.51M as of Dec 31, 2018
EBITDA (TTM): -$74.56M as of Dec 31, 2018
Net annual income (TTM): -$95.51M as of Dec 31, 2018
Free cash flow (TTM): -$109.10M as of Dec 31, 2018
Net Debt Last Fiscal Year: N/A
Shares outstanding: 628,148,866 as of Feb 26, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization